未登录

M

Marco Marzulli

university of pittsburgh

H指数:8

被引数:349

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Genetic mutations in HSV-1 replication-defective vectors: Implications for their safety in gene therapy applications

更正：HSV-1复制缺陷型载体中的基因突变：其在基因治疗应用中的安全性意义

IF4.5

2026-04-200

OAAI

Genetic mutations in HSV-1 replication-defective vectors: Implications for their safety in gene therapy applications

HSV-1复制缺陷型载体的基因突变：对基因治疗应用中其安全性的影响

IF4.5

2025-09-280

OAAI

Disease-modifying rdHSV-CA8*non-opioid analgesic gene therapy treats chronic osteoarthritis pain by activating Kv7 voltage-gated potassium channels

FRONTIERS IN MOLECULAR NEUROSCIENCE

IF3.8

2024-07-170

OAAI

rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels

FRONTIERS IN MOLECULAR NEUROSCIENCE

IF3.8

2024-05-093

OAAI

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment

MOLECULAR THERAPY-ONCOLYTICS

IF0

2021-09-014

OAAI

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

MOLECULAR THERAPY-ONCOLYTICS

IF0

2019-12-0135

OAAI

Arming a Tumor Targeted Oncolytic HSV Vector with MMP9 for Enhanced Distribution and Killing Activity

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

HSV Vectors Retargeted for Infection of TrkA Receptor-Bearing, Pain-Sensing C-Fibers

MOLECULAR THERAPY

IF12

2016-05-010

OAAI

Arming a tumor targeted oncolytic herpes simplex sirus type 1 with matrix metalloproteinase 9 for enhanced vector distribution and killing activity

CANCER RESEARCH

IF16.6

2015-08-010

PRE

HSV Vector-Mediated Expression of a Novel Drug Activated Pain Signalling Therapeutic Abrogates Pain

MOLECULAR THERAPY

IF12

2015-05-010

OAAI

Arming a Tumor Targeted Oncolytic Herpes Simplex Virus Type 1 With Matrix Metalloproteinase 9 for Enhanced Vector Distribution and Killing Activity

MOLECULAR THERAPY

IF12

2015-05-010

OAAI

HSV Vector Development for Targeted Gene Delivery

MOLECULAR THERAPY

IF12

2015-05-010

OAAI

Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV

MOLECULAR THERAPY

IF12

2015-01-0178

OAAI

HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA

IF13.4

2014-11-030

OAAI

Highly selective HSV virotherapy for glioblastoma

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus

MOLECULAR THERAPY

IF12

2013-03-01107

OA